Vivo Bio Tech profit slumps 86% even as revenue climbs 14%
Employee costs and depreciation erode margins in June quarter; net profit at ₹1.88 crore.
— 4 earlier stories on Vivo Bio Tech Ltd. →What's new
- Consolidated revenue rose 14% to ₹14.28 cr in June 2026 quarter.
- Net profit plunged 86% to ₹1.88 cr, hit by higher employee costs and depreciation.
- Results follow a ₹5.44 cr loss in Q4 FY26 and a recent promoter stake sale of 99%.
Why this matters
The profit collapse, combined with the promoter's near-complete exit and auditor flags on overdue dues, paints a deteriorating operating picture. The company has yet to provide any strategic response or guidance.
What we're watching
- Whether management addresses the cost structure in the coming quarters.
- Any further promoter share sales or stake changes.
- How the company plans to deal with overdue dues flagged by auditors.
The full read
Vivo Bio Tech's June quarter numbers are a mixed bag that leans adverse. Revenue rose 14% to ₹14.28 crore, but net profit collapsed 86% to ₹1.88 crore — a far cry from a year ago. The culprit: employee costs and depreciation, both jumping. That this profit (barely above a loss) comes on the heels of a ₹5.44 crore Q4 loss and a promoter who just sold 99% of its stake (4.51% of voting capital) makes the picture worse. The auditor had earlier flagged ₹4.19 crore in overdue dues. The filing itself is routine, but the numbers confirm a deteriorating business with no pivot in sight.
Questions answered
- Why did Vivo Bio Tech's profit drop so sharply despite higher revenue?
- Employee costs and depreciation rose more than revenue, squeezing margins. Net profit fell 86% to ₹1.88 crore from the year-earlier period.
- What is the company's recent track record?
- The prior quarter (Mar 2026) posted a net loss of ₹5.44 crore, and the auditor flagged ₹4.19 crore in overdue dues. The June quarter's profit is an improvement from loss but still sharply down year-on-year.
- Has the promoter sold shares recently?
- Yes, on June 8, 2026, the promoter sold 99% of its stake, amounting to 4.51% of voting capital.
- Is there any new guidance or strategic update in this filing?
- No. The filing is a routine quarterly result disclosure with no additional forward-looking statements.
Vivo Bio Tech Ltd.
Latest quarter · Jun 2026
Strength & growth
Story so far
All notes on VIVOBIOT →- 13 Jul 2026 · 7:43 PM IST Vivo Bio Tech profit slumps 86% even as revenue climbs 14%
- 10d ago Vivo Bio Tech profit plunges 86% despite 14% revenue growth
- 45d ago Vivo Bio Tech promoter sells 99% of its stake
- 54d ago Vivo Bio Tech posts ₹5.44 cr Q4 loss; auditor flags ₹4.19 cr in overdue dues
- 59d ago Vivo Bio Tech to consider merging a resort company into itself